These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22044409)

  • 21. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients.
    Masuda S; Inui K
    Pharmacol Ther; 2006 Oct; 112(1):184-98. PubMed ID: 16759707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.
    Anglicheau D; Legendre C; Beaune P; Thervet E
    Pharmacogenomics; 2007 Jul; 8(7):835-49. PubMed ID: 18240909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors.
    de Denus S; Zakrzewski M; Barhdadi A; Leblanc MH; Racine N; Bélanger F; Carrier M; Ducharme A; Dubé MP; Turgeon J; White M
    J Heart Lung Transplant; 2011 Mar; 30(3):326-31. PubMed ID: 21094057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calcineurin inhibitors in heart transplantation.
    Crespo-Leiro MG
    Transplant Proc; 2005 Nov; 37(9):4018-20. PubMed ID: 16386614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impaired erythropoietin production in liver transplant recipients: the role of calcineurin inhibitors.
    Bardet V; Junior AP; Coste J; Lecoq-Lafon C; Chouzenoux S; Bernard D; Soubrane O; Lacombe C; Calmus Y; Conti F
    Liver Transpl; 2006 Nov; 12(11):1649-54. PubMed ID: 17058250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetics of immunosuppressant polymorphism of CYP3A5 in renal transplant recipients.
    Larriba J; Imperiali N; Groppa R; Giordani C; Algranatti S; Redal MA
    Transplant Proc; 2010; 42(1):257-9. PubMed ID: 20172323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calcineurin Inhibitor Determination in Whole Blood With the RXL Dimension Analyzer: A Useful Tool for Immunosuppressive Drug Monitoring.
    Ventura E; Bonardet A; Pageaux GP; Mourad G; Cristol JP
    Transplant Proc; 2009 Mar; 41(2):707-9. PubMed ID: 19328963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine.
    Jardine AG
    Transpl Int; 2005 Apr; 18(4):379-84. PubMed ID: 15773954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Controversies about the use of calcineurin inhibitors in pediatric patients].
    Dello Strologo L
    G Ital Nefrol; 2008; 25(3):317-24. PubMed ID: 18473303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year.
    Rowshani AT; Scholten EM; Bemelman F; Eikmans M; Idu M; Roos-van Groningen MC; Surachno JS; Mallat MJ; Paul LC; de Fijter JW; Bajema IM; ten Berge I; Florquin S
    J Am Soc Nephrol; 2006 Jan; 17(1):305-12. PubMed ID: 16306168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenomics and transplantation: where are we?
    Frassetto LA; Benet LZ
    Am J Transplant; 2004 Jun; 4(6):843. PubMed ID: 15147415
    [No Abstract]   [Full Text] [Related]  

  • 32. The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation.
    Arora-Gupta N; Davies P; McKiernan P; Kelly DA
    Pediatr Transplant; 2004 Apr; 8(2):145-50. PubMed ID: 15049794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients.
    Balfour IC; Srun SW; Wood EG; Belsha CW; Marshall DL; Ferdman BR
    J Heart Lung Transplant; 2006 May; 25(5):518-22. PubMed ID: 16678029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increase in renal vascular resistance after intake of cyclosporin A and tacrolimus and reversal by nitroglycerin spray: a study in patients with stable renal allograft function.
    Weingart C; Leingärtner T; Bergler T; Krüger B; Böger C; Mack M; Banas B; Krämer BK
    Int J Clin Pharmacol Ther; 2006 Sep; 44(9):422-7. PubMed ID: 16995330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity.
    Hesselink DA; Bouamar R; van Gelder T
    Ther Drug Monit; 2010 Aug; 32(4):387-93. PubMed ID: 20571464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients.
    Min SI; Kim SY; Ahn SH; Min SK; Kim SH; Kim YS; Moon KC; Oh JM; Kim SJ; Ha J
    Transplantation; 2010 Dec; 90(12):1394-400. PubMed ID: 21076384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low tacrolimus dose requirements in renal transplant recipients in the omani population: implications for pharmacogenetics?
    Mohsin N; Pakkyara A; Budruddin M; Obaid F; Kumar A; Malvathu S; Kalankara S; Amitabh A; Daar A
    Transplant Proc; 2005 Sep; 37(7):2911-2. PubMed ID: 16213259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective, open-label, observational clinical cohort study of the association between delayed renal allograft function, tacrolimus exposure, and CYP3A5 genotype in adult recipients.
    Kuypers DR; de Jonge H; Naesens M; Vanrenterghem Y
    Clin Ther; 2010 Nov; 32(12):2012-23. PubMed ID: 21118736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PharmGKB summary: cyclosporine and tacrolimus pathways.
    Barbarino JM; Staatz CE; Venkataramanan R; Klein TE; Altman RB
    Pharmacogenet Genomics; 2013 Oct; 23(10):563-85. PubMed ID: 23922006
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.